MOVE-LVAD: Effects of Home-based Exercise Rehabilitation on Healthcare Utilization in HeartMate 3 Patients
Study Details
Study Description
Brief Summary
To demonstrate that home-based exercise rehabilitation (HER) compared to usual care (UC) results in a significant reduction in healthcare utilization in HeartMate 3 (HM3) left ventricular assist device (LVAD) patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Home-based Exercise Rehabilitation
|
Behavioral: Home-based Exercise Rehabilitation.
Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
|
| Active Comparator: Usual Care
|
Behavioral: Usual Care
Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
|
Outcome Measures
Primary Outcome Measures
- Mean number of clinic visits [1 year]
Healthcare utilization will be measured as the sum of all-cause rehospitalizations, outpatient VAD Clinic visits and emergency room visits room visits
Secondary Outcome Measures
- Mean number of days out of the hospital [1 year]
- Mean change in the number of daily steps taken [1 year]
Steps will be tracked using the Garmin watch. The Garmin watch uses Global Positioning System (GPS) tracking and an accelerometer to continuously monitor activity and provides data on average number of steps per day.
- Mean change 6-minute walk distance [baseline to 1 year]
- Mean change in number of participants with improved quality of life [baseline to 1 year]
Quality of life will be measured using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). The scale ranges from 12-70 with higher scores indicating better quality of life.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
≥ 18 years of age on the date of randomization
-
Patient implanted with a new HeartMate 3 LVAD at URMC
-
Patients enrolling in the study at the time of index discharge home following new HM3 LVAD implantation will be evaluated by a HF cardiologist and physical therapist and will need to demonstrate ability to ambulate independently. Patients enrolling in the study after their index discharge home following HM3 LVAD implantation will be evaluated by a HF cardiologist or VAD Coordinator and will need to demonstrate ability to ambulate independently.
-
Patient willing to participate in HER.
-
Patient owns a smartphone with Internet connection.
Exclusion Criteria:
-
Major comorbidities or limitations that may interfere with exercise training (including significant orthopedic/neurologic limitations, decompensated HF, uncontrolled arrhythmias, unstable angina).
-
Patient with a life expectancy <12 months.
-
Patient unwilling to sign the consent for participation.
-
Patient unwilling or unable to cooperate with the study protocol
-
Patient who does not anticipate being a resident of the area for the scheduled duration of the research study
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Rochester Medical Center | Rochester | New York | United States | 14642 |
Sponsors and Collaborators
- University of Rochester
- Abbott
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00004656